The Technical Analyst
Trillium Therapeutics [TRIL]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Trillium Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $18.44
/ 31 des 1970 @ 19:00
| RATING 2022-02-09 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 18.24 - 18.64 ( +/- 1.10%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-11-17 | Myers Scott Dunseth | Sell | 67 000 | Stock Option (Right to Buy) |
| 2021-11-17 | Beshar Luke M | Sell | 6 666 | Stock Option (Right to Buy) |
| 2021-11-17 | Beshar Luke M | Sell | 547 656 | Deferred Share Unit |
| 2021-11-17 | Beshar Luke M | Sell | 40 000 | Stock Option (Right to Buy) |
| 2021-11-17 | Parsons James T. | Sell | 36 204 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 94 transactions |
| Buy: 320 269 | Sell: 9 026 986 |
Forecast:
01:40 - $20.71
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $18.44 (0.00% ) |
| Volume | 26.17 mill |
| Avg. Vol. | 1.983 mill |
| % of Avg. Vol | 1 320.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TRIL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TRIL
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
Latest Press Releases
2021-08-24 13:00:00 - Press Release
Trillium Therapeutics Merger Investigation: Halper Sadeh Llp Announces Investigation Into Whether The Sale Of Trillium Therapeutics Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm – Tril
New york--(business wire)--halper sadeh llp, a global investor rights law firm, is investigating whether the sale of trillium therapeutics inc. (nasdaq: tril) to pfizer inc. for $18.50 per share in cash is fair to trillium shareholders. halper sadeh encourages trillium shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whether tri
2021-08-23 11:06:00 - Press Release
Trillium Therapeutics Merger Investigation: Halper Sadeh Llp Announces Investigation Into Whether The Sale Of Trillium Therapeutics Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm – Tril
New york--(business wire)--halper sadeh llp, a global investor rights law firm, is investigating whether the sale of trillium therapeutics inc. (nasdaq: tril) to pfizer inc. for $18.50 per share in cash is fair to trillium shareholders. halper sadeh encourages trillium shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whether tri
2021-08-23 06:45:00 - Press Release
Pfizer To Acquire Trillium Therapeutics Inc.
Proposed acquisition strengthens pfizer's category leadership in oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies
2021-08-13 07:00:00 - Press Release
Trillium Therapeutics Reports Second Quarter 2021 Operating And Financial Results
Cambridge, mass., aug. 13, 2021 (globe newswire) -- trillium therapeutics inc. (nasdaq/tsx: tril), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three and six months ended june 30, 2021. all financial amounts in this news release are in united states dollars, unless otherwise stated.
2021-08-09 07:00:00 - Press Release
Trillium Therapeutics Announces Dosing Of First Patient In Phase 1b/2 Study Of Tti-622 In Combination With Azacitidine In Tp53-mutated Acute Myeloid Leukemia
Cambridge, mass., aug. 09, 2021 (globe newswire) -- trillium therapeutics inc. (nasdaq/tsx: tril), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first tp53-mutated acute myeloid leukemia (aml) patient with tti-622 (sirpΑ-igg4 fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine.
Latest News
2023-08-03 09:22:48 - Proactive Investors
London capital markets have been surprisingly active in 2023, right?
Is it as grim as it seems for the City of London right now? Perhaps not, according to the London Stock Exchange's recent capital markets update for the first half of 2023.
2023-03-19 07:43:18 - Seeking Alpha
MDA Breakout Stocks/ETFs Week 12 - March 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 12 with better than 10% short-term upside with ETFs and a Dow 30 Pick. Average cumulative returns for 2023 are +37.3% YTD. The Momentum Gauges® continue negative in bear funds from Mar 7th led by BNKD +65.7%. EGO peaked at +8.3% gains for members.
2022-07-05 10:57:47 - Seeking Alpha
Week 27 MDA Breakout Stocks - July 2022: Short-Term Picks To Give You An Edge
Two new Breakout Stocks for Week 27 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +85.6% YTD.
2022-04-10 06:12:48 - Seeking Alpha
Week 15 MDA Breakout Stocks - April 2022: Short-Term Picks To Give You An Edge
2022-03-28 06:13:56 - Seeking Alpha
Week 13 MDA Breakout Stocks - April 2022: Short-Term Picks To Give You An Edge
Two sample Breakout Stocks for Week 13 with better than 10% short-term upside potential and a Dow stock pick.
2022-03-13 04:42:09 - Seeking Alpha
Week 11 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge
2022-03-06 08:26:41 - Seeking Alpha
Week 10 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge
2022-02-27 07:06:11 - Seeking Alpha
Week 9 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge
2022-02-20 06:17:07 - Seeking Alpha
Week 8 MDA Breakout Stocks - February 2022: Short-Term Picks To Give You An Edge
Two sample Breakout Stocks for Week 8 with better than 10% short-term upside potential and a Dow stock pick. The negative Momentum Gauge® signal continues into 2022 without a buy signal for the MDA breakout picks in one of the worst starts to the stock market since 2008.
2022-02-13 07:36:26 - Seeking Alpha
Week 7 MDA Breakout Stocks - February 2022: Short-Term Picks To Give You An Edge
